论文部分内容阅读
目的研究维吾尔族和汉族Ⅱb~Ⅳa期子宫颈癌患者治疗前后血清血管内皮生长因子(serum vascular endothelial growth factor,sVEGF)的改变,探讨其与临床病理特征的关系及在不同近期疗效、不同治疗手段中的变化规律。方法采用ELISA法定量检测44例Ⅱb~Ⅳa期子宫颈癌患者治疗前后sVEGF的表达水平,同时检测22例健康体检人群的sVEGF水平。治疗前患者与健康对照组采用成组t检验,治疗前后采用配对t检验。结果患者治疗前sVEGF水平明显高于健康对照组[(745.78±321.20)ng/L vs(169.79±123.17)ng/L,P<0.001]。治疗前sVEGF水平与FIGO分期、初诊时淋巴结转移、肿块大小及复发情况有关(均P<0.05),与族别、年龄、绝经状态、病理类型及分化程度均无关(均P>0.05)。治疗前sVEGF水平显著高于治疗后[(745.78±321.20)ng/L vs(361.12±307.32)ng/L,P<0.001)]。单纯放疗组及同期放化疗组治疗敏感组(CR+PR)治疗后sVEGF水平均显著降低(均P<0.001),而治疗耐受组(NC+PD)治疗前后的sVEGF水平无明显变化(P>0.05)。同期放化疗组较单纯放疗组sVEGF下降明显[(470.65±281.33)ng/L vs(316.84±186.71)ng/L,P<0.05)]。结论 sVEGF表达水平的变化对预测局部晚期子宫颈癌生物学行为有一定价值,可为疗效判断提供试验依据。局部晚期子宫颈癌同期放化疗后sVEGF水平较单纯放疗下降明显,抗VEGF靶向治疗在局部晚期子宫颈癌治疗中的应用值得研究。
Objective To study the changes of serum vascular endothelial growth factor (sVEGF) in patients with stage Ⅱb ~ Ⅳa cervical cancer before and after Uygur and Han ethnicity. To investigate the relationship between sVEGF and clinicopathological features, In the law of change. Methods The expression of sVEGF in 44 patients with stage Ⅱb-Ⅳa cervical cancer before and after treatment was detected by ELISA, and the sVEGF levels in 22 healthy people were also detected. Patients before treatment and healthy control group using t-test group, before and after treatment using paired t test. Results The level of sVEGF in patients before treatment was significantly higher than that in healthy controls [(745.78 ± 321.20) ng / L vs (169.79 ± 123.17) ng / L, P <0.001]. The level of sVEGF before treatment was correlated with FIGO staging, lymph node metastasis, tumor size and recurrence (all P <0.05). There was no correlation between sVEGF level and gender, age, menopausal status, pathological type and degree of differentiation (all P> 0.05). The level of sVEGF before treatment was significantly higher than that after treatment [(745.78 ± 321.20) ng / L vs (361.12 ± 307.32) ng / L, P <0.001). The level of sVEGF was significantly lower in both CR and PR + CR groups (all P <0.001), while there was no significant difference in sVEGF before and after CR + PR treatment (P + > 0.05). The sVEGF in the radiotherapy group was significantly lower than that in the radiotherapy alone group (470.65 ± 281.33 ng / L vs 316.84 ± 186.71 ng / L, P <0.05). Conclusion The change of sVEGF expression level has some value in predicting the biological behavior of locally advanced cervical cancer, which can provide the experimental basis for judging the curative effect. The sVEGF level of locally advanced cervical cancer after radiotherapy and chemotherapy is significantly lower than that of radiotherapy alone. The application of anti-VEGF targeted therapy in the treatment of locally advanced cervical cancer is worth studying.